title: Therapeutic use of the phosphate binder lanthanum carbonate.
abstract: Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control of serum phosphorus is accomplished with phosphate binder therapies that include calcium and aluminum salts. Recently, calcium-based binders have undergone reevaluation because of their association with cardiac calcification. The non-calcium, non-aluminum binder sevelamer hydrochloride has been associated with slower progression of cardiac calcification in clinical trials. Lanthanum carbonate is a newer phosphate binder with phosphate binding activity similar to aluminum salts making this agent a compelling alternative; however, more data are needed to evaluate long-term safety and effects on cardiovascular end points.
authors.affiliation: ANephRx-Albany Nephrology Pharmacy Group, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA. abartonpai@yahoo.com
authors.forename: Amy
authors.initials: A
authors.lastname: Barton Pai
authors.forename: Todd A
authors.initials: TA
authors.lastname: Conner
authors.forename: Charles R
authors.initials: CR
authors.lastname: McQuade
mesh_terms: D001842:Bone and Bones / Q000378:metabolism; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000378:metabolism; D007811:Lanthanum / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism; D010710:Phosphates / Q000737:chemistry* / Q000378:metabolism*
chemical_list: D010710:Phosphates; C119467:lanthanum carbonate; D007811:Lanthanum